Efficacy and safety of adalimumab in hidradenitis suppurativa: A systematic review and meta-analysis of randomized controlled trials

Adalimumab is used as a first-line biologic agent in the management of moderate-to-severe hidradenitis suppurativa (HS). The objective of the present study was to evaluate the efficacy and safety of adalimumab in patients with moderate-to-severe HS. We performed a systematic review and meta-analysis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medicine (Baltimore) 2021-06, Vol.100 (22), p.e26190-e26190
Hauptverfasser:	Lu, Jing-Wun, Huang, Yu-Wen, Chen, Tai-Li
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - administration & dosage Adalimumab - adverse effects Adalimumab - therapeutic use Adult Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Case-Control Studies Hidradenitis Suppurativa - drug therapy Hidradenitis Suppurativa - psychology Humans Injections, Subcutaneous Middle Aged Placebos - administration & dosage Quality of Life Randomized Controlled Trials as Topic Severity of Illness Index Systematic Review and Meta-Analysis Treatment Outcome Tumor Necrosis Factor Inhibitors - therapeutic use Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!